Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
This Phase II clinical trial is a monocenter, double-blind, randomized, placebo-controlled study aimed at evaluate the efficacy and safety of solriamfetol from 75 to 300 mg per day in IH patients. Patients will be randomized (1:1) to receive either solriamfetol or placebo, with titration, every morning upon awakening during all treatment periods (Day 0 to Week 7).
Epistemonikos ID: c559aa4c9b95fd5e500c69a4e8dd6f4cc2c76b52
First added on: Apr 17, 2025